← board
EVAX
Evaxion Biotech A/Sdistress 3/10 · well-funded / low risk$3.02-1%today-73% from 52w high
Oncology 1
Lead: Melanoma Stage IV · target PD-1 · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$18M
Runway
2.8 yrs
Shares 1y
0%
Price & events
-27.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-3.2%
1W
-10.9%
1M
-28.9%
3M
-25.2%
6M
+12.7%
1Y
-78.0%
2Y
-98.9%
5Y
-99.4%
All
Overview
- Market Cap
- $1.26B
- Enterprise Value
- $1.25B
- Volume
- 266
- 52 Week Range
- $2.54 – $11.01
- Total Shares
- 417.01M
- Float Shares
- 5.68M
- Short %
- 0.43%
- % Held by Insiders
- 17.47%
- % Held by Institutions
- 9.40%
- RVOL
- 0.01x
- Beta
- 0.26
Pipeline stages · 1 programs
EVX-01, Pembrolizumab 25 MG/MLPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09-30 | Phase 2 | EVX-01, Pembrolizumab 25 MG/ML | Melanoma Stage IV, Unresectable Melanoma | 17 | active not recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-24HC Wainwright & Co.Buy
- 2026-03-10Jones TradingBuy
- 2026-03-09Lake StreetBuy
- 2026-03-09HC Wainwright & Co.Buy
- 2025-10-30Edward JonesBuy
- 2025-10-20HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-20Evaxion Presents New Preclinical Data for AI-Designed CMV Vaccine Program EVX-V1 - The Hearing Review
- 2026-07-20Price to book forward of Evaxion A/S – NASDAQ:EVAX - TradingView
- 2026-07-19Evaxion A/S | 3/A: Initial statement of beneficial ownership of securities (Amendment)- Mattsson Andreas Holm - Moomoo
- 2026-07-17Evaxion to present three-year EVX-01 melanoma trial data at ESMO By Investing.com - Investing.com South Africa
- 2026-07-17Evaxion (NASDAQ: EVAX) to share 3-year EVX-01 melanoma trial results at ESMO 2026 - Stock Titan
- 2026-07-17Evaxion to present three-year EVX-01 melanoma trial data at ESMO - Investing.com
- 2026-07-17Evaxion to Present Three-Year Phase 2 Data for EVX-01 in Advanced Melanoma at ESMO 2026 - Quiver Quantitative
- 2026-07-17Evaxion's personalized cancer vaccine showed a 75% response rate in melanoma - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.